SecBot SecBot

EDVA

Endovia Health Sciences, Inc.
NYSE· CIK 0001553788
$0.1598 −0.00 (−0.13%)
Oct 26 4:00 PM ET · prev $0.1600
Market cap
$1.7M
Nano cap
Next earnings
Nov 17
in 22 days
1 year
−98.0%
from $7.80 · Oct 27
30 days
−14.5%
from $0.1870
52-week range
$0.1350–8.28
−98% from high · low Oct 19
Avg volume 20D
891.6K
Oct 5 spike 9.04M
Short interest
173.9K
≈1.6% of shares · −48.8%
Days to cover
1.0
at average volume
Filing reports
7
analyzed by SecBot
SecBot read BEARISH 7 reports · 90 days
Balance 4 bearish · 1 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 5/7 ·Next Earnings date, Nov 17, 2026
Strongest BEARISH Endovia Health Sciences is seeking stockholder approval at its November 20, 2026 annual meeting for a highly…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • Short sellersCOVERING

    Short interest −48.8% to 173.9K shares. 1.0 days to cover, ≈1.6% of shares.

  • TrendDOWNTREND

    33% below its 50-day average.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
C/M Capital Partners, LP and related entities filed a Schedule 13G disclosing a passive 7.2% stake in Endovia Health…
SC 13G — Impact 4/10
Oct 15, 2026 SEC
Endovia Health Sciences amended its equity line of credit (ELOC) agreement with C/M Capital Master Fund, LP…
8-K — Impact 5/10
Oct 6, 2026 SEC
Endovia Health Sciences issued 526,582 shares to C/M Capital Master Fund, LP under its existing ELOC agreement for…
8-K — Impact 6/10
Oct 5, 2026 Other
Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway
Endovia Health Sciences to Meet Formally with FDA’s Center for Veterinary Medicine on November 19th

Earnings setup

Estimates
Nov 17
reports in 22 days
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY———$0.00
Next FY———$0.00

Short side

FINRA· Sep 30, 2026
173,903
shares short
-48.8%
vs prior settlement
1.0
days to cover
≈1.6%
of shares outstanding
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 17, 2026
Earnings date
EDVA Q3 2026 Earnings Scheduled — 2026-11-17
Recent
Oct 5, 2026
Press release
Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway
Endovia Health Sciences to Meet Formally with FDA’s Center for Veterinary Medicine on November 19th for Pre-Submission Conference
Sep 22, 2026
Press release
Endovia Health Sciences Closes Initial Funding to Accelerate CannEpil® Development Amid Growing Federal Support for Botanical Drug Pathways
Endovia financing comes as FDA and Congress increase focus on advancing and incentivizing regulated development of botanical and plant-derived…
Aug 31, 2026
Press release
Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline
Endovia Health Sciences believes the federal government’s affirmative support for Schedule III represents a significant evolution in U.S…
Aug 24, 2026
Listing
New Listing: EDVA — Endovia Health Sciences, Inc. Common Stock
Listed on exchange A

SecBot reports

7 filings · 1 bullish · 4 bearish · 2 neutral
All EDVA filing & press-release reports (7)